Company:  TRIUS THERAPEUTICS INC
Form Type:  10-Q
Filing Date:  8/7/2012 
CIK:  0001356857 
Address:  6310 NANCY RIDGE DR SUITE 105 
City, State, Zip:  SAN DIEGO, California 92121 
Telephone:  858-452-0370 
Fiscal Year:  12/31 
Description of Business
We are a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibiotics for serious infections. We are developing tedizolid phosphate, a new, novel antibiotic, for the treatment of serious Gram-positive bacterial infections, including those caused by methicillin-resistant staphylococcus aureus, or MRSA. Tedizolid phosphate is being developed for acute bacterial skin and skin structure infections, or ABSSSI, and pneumonia, and potentially for other indications. ABSSSI is the current classification for complicated skin and skin structure infections. In addition, we are discovering antibiotics for infections caused by Gram-negative bacteria using our structure based discovery platform. In December 2011, we reported top line data from our first Phase 3 clinical trial, the ESTABLISH 1 (TR701-112) study, of the oral dosage form of tedizolid phosphate for the treatment of ABSSSI.
Register for EDGAR Pro and access this filing in:     
  FORM 10-Q
    PART I. FINANCIAL INFORMATION
      Item 1. Financial Statements
        BALANCE SHEET
        INCOME STATEMENT
        CASH FLOW
        NOTES TO FINANCIAL STATEMENTS
      Item 2. Management's Discussion and Analysis of Financial ...
      FINANCIAL STATEMENTS
        CASH FLOW
      Item 3. Qualitative and Quantitative Disclosures About ...
      Item 4. Controls and Procedures
    PART II. OTHER INFORMATION
      Item 1A. Risk Factors
      Item 4. Mine Safety Disclosures
      Item 6. Exhibits
    EXHIBIT INDEX
    SIGNATURES
  EXHIBIT 31.1
    CERTIFICATION PURSUANT
  EXHIBIT 31.2
    CERTIFICATION PURSUANT
  EXHIBIT 32.1
    CERTIFICATION PURSUANT TO
  EXHIBIT 32.2
    CERTIFICATION PURSUANT TO
BROKERAGE PARTNERS